IMAC Holdings Inc, a provider of Innovative Medical Advancements and Care, specializing in regenerative and rehabilitation orthopedic treatments without the use of surgery or opioids, announces new data showing long-term post-treatment outcomes for 130 regenerative-rehabilitation patients treated at IMAC Regeneration Centers.

Musculoskeletal conditions treated included 45 knee patients, 42 spine patients and 43 patients with multiple and other conditions (shoulder, hip, elbow, thigh, wrist, thumb, calf and/or ankle). Data collection averaged 17.3 months post-treatment with an average patient age of 61.7 years. Outcomes data was collected through the Functional Rating Index (FRI), National Pain Scale (NPS) and Single Assessment Numeric Evaluation (SANE).

The long-term outcomes data include:

  • 56% improvement in optimal function to 77% from 49% function;
  • 50% improvement in quality of life to 80% from 54%; and
  • 46% reduction in pain to 34% from 63%.

Patients completed care at least 11 months and at most 25 months prior to the data collection date, the company notes in a media release.

“This outcomes data provides compelling support for our combined regenerative and rehabilitative treatments, which provide patients an alternative to surgery and opioids for the treatment of pain,” says Matthew Wallis, cofounder and chief operating officer of IMAC.

“The outcomes demonstrate that improvements were similar across all joint functions that we measured, including knee, spine, shoulders and hips. Nearly all of these patients qualified for a surgical intervention and only two of the 130 patients still required surgery, which we view as an excellent outcome. In addition, pain relief scores were impressive across the board.”

Commenting on the study, Jeff Ervin, IMAC’s chief executive officer, adds, “These results show our success as an alternative to orthopedic surgery. We are working to publish this data in the coming months and look forward to sharing this data with self-insured employers seeking cost-reduction solutions to rising healthcare expenditures.

“Additionally, we expect this data to serve as a foundation for expanding services to other movement-restricting conditions as we continue to develop evidence-based medical protocols.”

[Source(s): IMAC Holdings Inc, GlobeNewswire]